Company intelligence / Profile preview

ValenzaBio

Bethesda, Maryland, United Statescrunchbase.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ValenzaBio advanced a pipeline of differentiated monoclonal antibodies for autoimmune and inflammatory diseases including membranous nephropathy (lead program, VB119) and thyroid eye disease (VB421). As of acquisition, lead programs were at or nearing Phase 2 development. Clinical results indicated safety and initial efficacy, but detailed public data is limited.

Therapeutic areas: NephrologyEndocrinologyImmunology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

3 assets

VB119

Phase 1

Indications: Membranous nephropathy, Autoimmune diseases

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ValenzaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ValenzaBio.

Explore the full profile